POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN’S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
Repatha is the Only PCSK9 Inhibitor Proven to Significantly Reduce Risk of First Heart Attack and Stroke in Phase 3 Clinical Trial, Setting a New Benchmark in Cardiovascular Risk Reduction Recommendation Based
